A UTILIZAÇÃO DA TOXINA BOTULÍNICA DO TIPO A PARA TRATAMENTO DA ENXAQUECA CRÔNICA: Uma revisão de literatura
DOI:
https://doi.org/10.61164/rsv.v7i1.1958Resumo
INTRODUÇÃO: A onabotulinumtoxinA (OnaB-A) vem se destacando como uma nova terapia de tratamento preventivo para a enxaqueca crônica, surgindo em fase de observações clínicas, a qual vem sendo apoiada no presente momento por evidências de mais de um década de pesquisas e dados clínicos no mundo real. No presente momento a capacidade de prever as respostas são limitadas, embora que os pacientes sejam clinicamente significativos ainda há um caminho a ser percorrido. Esta revisão resume brevemente as atualizações sobre o uso da onabotulinumtoxinA na terapia preventiva da enxaqueca crônica, bem como esclarece as principais divergências acerca da dose, tipos de respondedores e início do tratamento. OBJETIVO: Analisar as atualizações acerca do uso a onabotulinumtoxinA para o tratamento da enxaqueca crônica. METODOLOGIA: Trata-se de uma revisão de literatura, descritiva, com abordagem qualitativa, realizada nas seguintes bases de dados: PubMed e BVS, utilizando os seguintes termos de busca: OnabotulinumtoxinA (OnaB-A) e Chronic Migraine. Foram incluídos os artigos dos seguintes idiomas: francês, inglês e português. CONCLUSÃO: Portanto, conclui-se que a aplicação da OnabotulinumtoxinA diminui o número de dias de cefaleia e a intensidade da dor, embora ainda seja considerada recente, o BT-A é um tratamento profilático, preventivo, seguro e eficaz para a enxaqueca crônica.
Palavras-chaves: Toxina botulínica A, OnabotulinumtoxinA (OnaB-A), Enxaqueca crônica e Chronic Migraine
Referências
Bendtsen, L., et al. Diretriz sobre o uso de onabotulinumtoxinA na enxaqueca crônica: uma declaração de consenso da European Headache Federation. J Headache Pain 19, 91 (2018). https://doi.org/10.1186/s10194-018-0921-8 DOI: https://doi.org/10.1186/s10194-018-0921-8
Blumenfeld, A. M., et al (2019). Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. Journal of neurology, neurosurgery, and psychiatry, 90(3), 353–360. https://doi.org/10.1136/jnnp-2018-319290 DOI: https://doi.org/10.1136/jnnp-2018-319290
Boudreau, G., et al (2022). OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 49(4), 540–552. https://doi.org/10.1017/cjn.2021.153 DOI: https://doi.org/10.1017/cjn.2021.153
Caronna, E., et al (2018). OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse. Frontiers in neurology, 9, 808. https://doi.org/10.3389/fneur.2018.00808 DOI: https://doi.org/10.3389/fneur.2018.00808
Colhado, O. C. G., et al (2009). Toxina botulínica no tratamento da dor. Revista Brasileira de Anestesiologia, 59, 366-381.
Dodick, D. W., et al (2019). Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. Cephalalgia : an international journal of headache, 39(8), 945–956. https://doi.org/10.1177/0333102418825382 DOI: https://doi.org/10.1177/0333102418825382
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589–600. https://doi.org/10.1007/s40265-018-0894-6 DOI: https://doi.org/10.1007/s40265-018-0894-6
Gandolfi, M., et al (2019). A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. Toxins, 11(9), 504. https://doi.org/10.3390/toxins11090504 DOI: https://doi.org/10.3390/toxins11090504
Grazzi, L., et al (2023). A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role. Toxins, 15(2), 86. https://doi.org/10.3390/toxins15020086 DOI: https://doi.org/10.3390/toxins15020086
Kim, K. M., et al (2021). Prevalence, Disability, and Management Patterns of Migraine in Korea: Nationwide Survey Data from 2009 and 2018. Journal of clinical neurology (Seoul, Korea), 17(1), 77–85. https://doi.org/10.3988/jcn.2021.17.1.77 DOI: https://doi.org/10.3988/jcn.2021.17.1.77
Matak, I., et al (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11(8), 459. https://doi.org/10.3390/toxins11080459 DOI: https://doi.org/10.3390/toxins11080459
Onan, D., et al (2022). OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity. Toxins, 15(1), 29. https://doi.org/10.3390/toxins15010029 DOI: https://doi.org/10.3390/toxins15010029
Ornello R, et al. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain Ther. 2021 Jun;10(1):637-650. doi: 10.1007/s40122-021-00253-0. Epub 2021 Mar 28. PMID: 33778933; PMCID: PMC8119503.
Ornello, R., et al (2021). Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and therapy, 10(1), 637–650. https://doi.org/10.1007/s40122-021-00253-0 DOI: https://doi.org/10.1007/s40122-021-00253-0
Ornello, R., et al (2022). Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors. International journal of environmental research and public health, 19(17), 10975. https://doi.org/10.3390/ijerph191710975 DOI: https://doi.org/10.3390/ijerph191710975
Santoro, A., et al (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809–1820. https://doi.org/10.1007/s10072-020-04283-y DOI: https://doi.org/10.1007/s10072-020-04283-y
Schiano di Cola F, et al 2019 Jul 10;10:678. Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment. doi: 10.3389/fneur.2019.00678. PMID: 31354606; PMCID: PMC6635602. DOI: https://doi.org/10.3389/fneur.2019.00678
Torrente, A., et al (2022). OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment. Toxins, 15(1), 23. https://doi.org/10.3390/toxins15010023 DOI: https://doi.org/10.3390/toxins15010023
Torres-Ferrus, M., et al (2020). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. https://doi.org/10.1186/s10194-020-01157-8
Torres-Ferrus, M., et al (2020). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. https://doi.org/10.1186/s10194-020-01157-8 DOI: https://doi.org/10.1186/s10194-020-01157-8
Valente, M., et al (2021). Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine. Toxins, 13(6), 392. https://doi.org/10.3390/toxins13060392 DOI: https://doi.org/10.3390/toxins13060392
Vikelis, M., et al (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. https://doi.org/10.1186/s10194-018-0918-3 DOI: https://doi.org/10.1186/s10194-018-0918-3
Wilderman, I., et al (2021). A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine. Pain and therapy, 10(2), 1523–1536. https://doi.org/10.1007/s40122-021-00316-2 DOI: https://doi.org/10.1007/s40122-021-00316-2
Winner P.K., et al. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019 Aug;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3. PMID: 31102144; PMCID: PMC6647876. DOI: https://doi.org/10.1007/s40264-019-00824-3
Zandieh, A., & Cutrer, F. M. (2022). OnabotulinumtoxinA in chronic migraine: is the response dose dependent?. BMC neurology, 22(1), 218. https://doi.org/10.1186/s12883-022-02742-x DOI: https://doi.org/10.1186/s12883-022-02742-x
